About this medicine

Clonazepam reduces excessive nervous-system activity. NHS patient information also describes use for panic symptoms and movement-related problems, but this does not expand its UK product licence.

The important regional difference is the purpose of treatment. American panic-disorder approval does not establish a UK panic licence, and short-term anxiety prescribing principles must not be mechanically applied to necessary long-term epilepsy treatment. The exact formulation and seizure plan remain central.

What is this medicine used for?

Aristo tablets are licensed for several forms of epilepsy. The checked Thame liquid has narrower seizure wording. Neither label licenses panic disorder; NICE advises against benzodiazepines for treating panic disorder.

The Aristo tablet licence includes absence, generalised tonic-clonic, focal and myoclonic seizure presentations in infants, children and adults. This broad tablet wording is not permission to diagnose a seizure type or to transfer the same indication to a different liquid. Panic and sleep-related uses require an explicitly separate off-label assessment.

Which warning signs need help?

Sudden withdrawal can provoke severe seizures. Opioids and alcohol increase the risk of deep sedation, coma and breathing failure. Seek emergency care for inability to wake, abnormal breathing or a prolonged seizure: 999 in the UK, local emergency services elsewhere.

Physical dependence is adaptation that can produce withdrawal after abrupt reduction; addiction involves impaired control and continued use despite harm. They are related but not identical, and can occur during prescribed treatment. Discuss concerns without blame. New suicidal thinking or major behavioural change needs prompt assessment.

How do I take it safely?

For adult epilepsy, the Aristo label starts at no more than 1 mg daily, with gradual adjustment; usual maintenance is 4–8 mg daily. These are epilepsy schedules, not panic-disorder doses. The checked liquid contains ethanol and is not indicated for children.

The UK tablet schedule uses low initial divided doses, with maintenance generally reached over two to four weeks. Older adults start more cautiously. Paediatric epilepsy requires specialist adjustment using suitable strengths; the American panic regimen and orally disintegrating product strengths are not UK instructions.

What side effects should I know about?

Drowsiness, dizziness, tiredness and muscle weakness are recognised effects. Unusual agitation or worsening mood needs review. Children may develop increased saliva or airway secretions and require close observation.

Sleepiness or unsteadiness may interfere with walking, school, work or driving. Record changes after dose adjustments and report falls or excessive sedation. A person may be less aware of impairment than a family member or carer, so observations can help the review.

Who needs extra care with this medicine?

Sleep apnoea, severe respiratory or liver insufficiency and myasthenia gravis are contraindications in the checked tablet label. Older people, and people with substance-use or mental-health concerns, need careful assessment.

Respiratory disease, frailty, kidney or liver impairment, swallowing or secretion difficulties and a history of depression warrant particular care. The combination of existing vulnerability and another sedative can be more important than either factor alone.

Can it affect my other medicines?

Other sedating medicines can intensify effects. Antiseizure medicines may alter clonazepam exposure; combinations require individual review. Avoid alcohol and tell the clinician about every prescribed, non-prescribed and recreational substance.

Interactions are not limited to prescription sleeping tablets: opioid painkillers, alcohol and other sedating substances can suppress breathing together. Antiseizure combinations also need review for altered exposure and combined adverse effects; two medicines treating seizures are not automatically compatible.

What check-ups will I need?

Review seizure control, sedation, falls, mood and tolerance. Routine clonazepam blood levels are not a reliable substitute for assessing clinical response and adverse effects.

Follow seizure frequency, alertness, breathing concerns, mood and practical functioning. Reassess the continuing dose and formulation with the epilepsy team. Blood concentration alone cannot determine whether benefit outweighs sedation, falls or behavioural effects.

What about pregnancy, breastfeeding and age?

Pregnancy planning should involve the epilepsy team; abruptly stopping can also be dangerous. Newborn effects and breastfeeding require assessment. Tablet paediatric indications must not be transferred to the ethanol-containing Thame liquid.

If pregnancy is planned or occurs, contact the epilepsy team promptly rather than stopping independently. The balance includes seizure control and possible newborn sedation or withdrawal. Older adults are more vulnerable to confusion and falls and usually need closer observation.

What if I miss a dose or want to stop?

Follow a personalised reduction plan when stopping. Epilepsy treatment may remain necessary long term. For the Aristo tablets, skip a forgotten dose and take the next at its usual time; never double it.

An interruption can cause both withdrawal and loss of seizure protection. Contact the team about repeated missed doses or inability to take treatment. The need to minimise dependence does not mean that every epilepsy prescription should end after an arbitrary few weeks.

How does it work?

Clonazepam strengthens the effect of GABA, a chemical messenger that helps quiet nerve-cell activity. GABA attaches to a receiving protein called the GABA-A receptor, making the cell less likely to send another electrical signal. This restraint on activity is called inhibition and is a normal part of how brain cells communicate.

Clonazepam attaches to a separate part of that receptor, the benzodiazepine site, and makes the response to GABA stronger. This helps explain its seizure-suppressing, calming and muscle-relaxing effects, as well as sleepiness and reduced coordination. Its precise clinical mechanism is not fully worked out, and a calming response does not show that someone had a measurable shortage of GABA.

How does it affect my body?

Sleepiness, slowed reactions and reduced coordination can affect everyday activities. Seizure control may develop gradually while the dose is adjusted; early sedation does not measure long-term benefit.

Alertness, memory and balance can be affected along with seizure activity. Occasionally the response is paradoxical, with agitation or disinhibition rather than calm. Tolerance may develop, but loss of benefit is a reason for specialist review, not independent escalation.

How does my body process it?

The liver metabolises clonazepam. Its elimination half-life is roughly 20–60 hours, so it can accumulate and its effects can extend beyond one dosing interval.

The long elimination period means repeated doses can accumulate. Feeling that an earlier dose has worn off is not proof that little medicine remains in the body. Liver disease and other medicines can change exposure; a half-life is not a personal guide to dose spacing.

How do treatment options differ?

Clonazepam is longer acting than lorazepam. Similar membership of the benzodiazepine family does not make their licensed indications, doses or stopping schedules equivalent.

A closer look at the science

It acts as a positive allosteric modulator: binding changes the receptor’s response to GABA, increasing GABA-associated chloride-ion movement. This is a receptor effect, not replacement of a missing brain chemical.

Allosteric means binding at a site that changes how another site responds. In this case the drug changes GABA-A receptor activity rather than acting as a simple replacement transmitter. The molecular action does not make benzodiazepine tablets interchangeable by milligram strength.

How was this medicine developed?

Klonopin remains a cross-edition search alias. This UK record concerns Aristo tablets and Thame oral solution; neither checked UK product licenses panic disorder.

The US Klonopin history includes a panic indication that is not carried by the checked UK tablets or liquid. Current UK information explicitly discusses dependence and addiction while preserving treatment for as long as epilepsy management requires.

Sources and References

  1. NHS: common questions about clonazepam

    Scope: NHS.uk public information (England); not a statement of uniform services or funding across the four UK nations.

  2. Clonazepam Aristo 0.5 mg tablets — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Clonazepam Thame 0.5 mg/5 ml oral solution — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. NICE CG113: generalised anxiety and panic disorder — drug-treatment recommendations on benzodiazepines

    Scope: NICE guidance (England-based); applicability and implementation in other UK nations require the relevant national pathway.

  5. Clonazepam Aristo 0.5 mg and 2 mg tablets — patient leaflet, sections 1–4 and 6

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  6. Oral benzodiazepines and choosing equivalent doses — differences and licensed indications

    Scope: NHS Specialist Pharmacy Service (England); not a UK-wide commissioning or legal rule.

  7. Klonopin tablets: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology: Pharmacodynamics and Pharmacokinetics; Drug Abuse and Dependence: Dependence. This does not establish UK product authorisation or prescribing..

  8. Clonazepam: MedlinePlus Drug Information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?; Important warning. This does not establish UK product authorisation or prescribing..

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top